The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients
Open accessAbstract
OBJECTIVES: To assess efficacy and safety of rituximab (RTX) as induction therapy, maintenance of remission and treatment of relapses in a cohort of IgG4-related disease (IgG4-RD) patients. METHODS: Nationwide retrospective multicenter study of IgG4-RD patients treated with at least one course of RTX. Clinical, biological and radiological response, relapse rate and drug tolerance were analyzed. Kaplan-Meier curves were plotted and risk factors for relapse studied with a Cox regression model. RESULTS: Among 156 IgG4-RD patients included in the French database, 33 received rituximab. Clinical response was noted in 29/31 (93.5%) symptomatic patients. Glucocorticoids withdrawal was achieved in 17 (51.5%) patients. During a mean follow-up of 24.8 ±21 months, 13/31 (41.9%) responder patients relapsed after a mean delay of 19 ±11 months after RTX. Active disease, as defined by an IgG4-RD Responder Index >9 before RTX, was significantly associated with relapse (HR = 3.68, 95% CI: 1.1, 12.6) (P = 0.04), whereas maintenance therapy with systematic (i.e. before occurrence of a relapse) RTX retreatment was associated with longer relapse-free survival (41 versus 21 months; P = 0.02). Eight severe infections occurred in 4 patients during follow-up (severe infections rate of 12.1/100 patient-years) and hypogammaglobulinemia ≤5 g/l in 3 patients. CONCLUSION: RTX is effective for both induction therapy and treatment of relapses in IgG4-RD, but relapses are frequent after B-cell reconstitution. Maintenance therapy with systematic RTX infusions is associated with longer relapse-free survival and might represent a novel treatment strategy. Yet, the high rate of infections and the temporary effect of RTX might be hindrances to such strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Stone, J. H., Zen, Y., & Deshpande, V. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1104650 · Cited by 2,616
Consensus statement on the pathology of IgG4-related disease
Deshpande, V., Zen, Y., Chan, J. K., Yi, E. E., Sato, Y., Yoshino, T., Klöppel, G., Heathcote, J. G., Khosroshahi, A., Ferry, J. A., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.72 · Cited by 2,596
Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011
Umehara, H., Okazaki, K., Masaki, Y., Kawano, M., Yamamoto, M., Saeki, T., Matsui, S., Yoshino, T., Nakamura, S., Kawa, S., et al. (2012) · Modern Rheumatology · doi:10.1007/s10165-011-0571-z · Cited by 2,028
Shimosegawa, T., Chari, S. T., Frulloni, L., Kamisawa, T., Kawa, S., Mino-Kenudson, M., Kim, M.-H., Klöppel, G., Lerch, M. M., Löhr, M., et al. (2011) · Pancreas · doi:10.1097/mpa.0b013e3182142fd2 · Cited by 1,526
Kamisawa, T., Zen, Y., Pillai, S., & Stone, J. H. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60720-0 · Cited by 1,212
Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
Guillevin, L., Pagnoux, C., Karras, A., Khouatra, C., Aumaître, O., Cohen, P., Maurier, F., Decaux, O., Ninet, J., Gobert, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404231 · Cited by 1,090
Self-citationInternational Consensus Guidance Statement on the Management and Treatment of IgG4‐Related Disease
Khosroshahi, A., Wallace, Z. S., Crowe, J. L., Akamizu, T., Azumi, A., Carruthers, M. N., Chari, S. T., Della‐Torre, E., Frulloni, L., Goto, H., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39132 · Cited by 1,064
Self-citationRituximab for IgG4-related disease: a prospective, open-label trial
Carruthers, M. N., Topazian, M. D., Khosroshahi, A., Witzig, T. E., Wallace, Z. S., Hart, P. A., Deshpande, V., Smyrk, T. C., Chari, S., & Stone, J. H. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206605 · Cited by 726
IgG4‐Related Disease: Clinical and Laboratory Features in One Hundred Twenty‐Five Patients
Wallace, Z. S., Deshpande, V., Mattoo, H., Mahajan, V. S., Kulikova, M., Pillai, S., & Stone, J. H. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39205 · Cited by 666
Cited by
Beyer, G., Habtezion, A., Werner, J., Lerch, M. M., & Mayerle, J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31318-0 · Cited by 506
IgG4-related disease: an update on pathophysiology and implications for clinical care
Perugino, C. A., & Stone, J. H. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0500-7 · Cited by 421
Advances in the diagnosis and management of IgG4 related disease
Lanzillotta, M., Mancuso, G., & Della-Torre, E. (2020) · BMJ · doi:10.1136/bmj.m1067 · Cited by 360
The Role of B Cells and B Cell Therapies in Immune-Mediated Liver Diseases
Cargill, T., & Culver, E. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661196 · Cited by 46
Goodchild, G., Peters, R. J., Cargill, T. N., Martin, H., Fadipe, A., Leandro, M., Bailey, A., Collier, J., Firmin, L., Chouhan, M., et al. (2020) · Clinical Medicine · doi:10.7861/clinmed.2019-0457 · Cited by 13
Metadata
- Authors
- Ebbo, M., Grados, A., Samson, M., Groh, M., Loundou, A., Rigolet, A., Terrier, B., Guillaud, C., Carra-Dallière, C., Renou, F., Pozdzik, A., Labauge, P., Palat, S., Berthelot, J.-M., Pennaforte, J.-L., Wynckel, A., Lebas, C., Le Gouellec, N., Quémeneur, T., Dahan, K., Carbonnel, F., Leroux, G., Perlat, A., Mathian, A., Cacoub, P., Hachulla, E., Costedoat-Chalumeau, N., Harlé, J.-R., & Schleinitz, N.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-09-15
- Volume
- 12
- Issue
- 9
- Pages
- e0183844
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2755478460
- Cited by
- 253
- References
- 43
- FWCI
- 17.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. https://app.cochat.ai/papers/10.1371/journal.pone.0183844
- The paper
- Ebbo, M., Grados, A., Samson, M., Groh, M., Loundou, A., Rigolet, A., Terrier, B., Guillaud, C., Carra-Dallière, C., Renou, F., Pozdzik, A., Labauge, P., Palat, S., Berthelot, J.-M., Pennaforte, J.-L., Wynckel, A., Lebas, C., Le Gouellec, N., Quémeneur, T., . . . Schleinitz, N. (2017). Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. PLOS ONE. https://doi.org/10.1371/journal.pone.0183844
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.